Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Beth Faiman

Showing results (51-60 of 59) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 59 results.
Journal of Clinical Medicine|September 9, 2023
Management of Adverse Reactions for BCMA-Directed Therapy in Relapsed Multiple Myeloma: A Focused ReviewRazwana Khanam, Beth Faiman, Saba Batool, et al.
Cancer Research Communications|June 3, 2026
Multiple Myeloma Screening Education: A Community-Based Health Literacy InterventionKarie Feldman, Hong Li, Diana Basali, et al.
British Journal of Haematology|May 17, 2021
Validation of the IMPEDE VTE score for prediction of venous thromboembolism in multiple myeloma: a retrospective cohort studyFahrettin Covut, Ramsha Ahmed, Sanchit Chawla, et al.
Mayo Clinic Proceedings|December 14, 2005
The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myelomaRachid Baz, Liang Li, Kandice Kottke-Marchant, et al.
Patient Preference and Adherence|October 24, 2024
Patient, Care Partner, and Physician Voices in Treatment Decision-Making for Multiple MyelomaLisa Dwyer Orr, Dee Lin, Bingcao Wu, et al.
Clinical Lymphoma, Myeloma & Leukemia|July 29, 2014
Identifying professional education gaps and barriers in multiple myeloma patient care: findings of the Managing Myeloma Continuing Educational Initiative Advisory CommitteeNoopur Raje, Beth Faiman, R Donald Harvey, et al.
Blood Cancer Journal|May 31, 2024
Impact of Extraosseous Extramedullary Disease on Outcomes of Patients with Relapsed-Refractory Multiple Myeloma receiving Standard-of-Care Chimeric Antigen Receptor T-Cell TherapyDanai Dima, Al-Ola Abdallah, James A Davis, et al.
American Journal of Hematology|November 26, 2013
Mature results of MM-011: a phase I/II trial of liposomal doxorubicin, vincristine, dexamethasone, and lenalidomide combination therapy followed by lenalidomide maintenance for relapsed/refractory multiple myelomaAleksandr Lazaryan, Mohamad A Hussein, Frederic J Reu, et al.
Clinical Journal of Oncology Nursing|May 21, 2008
Management of side effects of novel therapies for multiple myeloma: consensus statements developed by the International Myeloma Foundation's Nurse Leadership BoardPage Bertolotti, Elizabeth Bilotti, Kathleen Colson, et al.
Pageof 6

Showing results (51-60 of 59) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 59 results.
Journal of Clinical Medicine|September 9, 2023
Management of Adverse Reactions for BCMA-Directed Therapy in Relapsed Multiple Myeloma: A Focused ReviewRazwana Khanam, Beth Faiman, Saba Batool, et al.
Cancer Research Communications|June 3, 2026
Multiple Myeloma Screening Education: A Community-Based Health Literacy InterventionKarie Feldman, Hong Li, Diana Basali, et al.
British Journal of Haematology|May 17, 2021
Validation of the IMPEDE VTE score for prediction of venous thromboembolism in multiple myeloma: a retrospective cohort studyFahrettin Covut, Ramsha Ahmed, Sanchit Chawla, et al.
Mayo Clinic Proceedings|December 14, 2005
The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myelomaRachid Baz, Liang Li, Kandice Kottke-Marchant, et al.
Patient Preference and Adherence|October 24, 2024
Patient, Care Partner, and Physician Voices in Treatment Decision-Making for Multiple MyelomaLisa Dwyer Orr, Dee Lin, Bingcao Wu, et al.
Clinical Lymphoma, Myeloma & Leukemia|July 29, 2014
Identifying professional education gaps and barriers in multiple myeloma patient care: findings of the Managing Myeloma Continuing Educational Initiative Advisory CommitteeNoopur Raje, Beth Faiman, R Donald Harvey, et al.
Blood Cancer Journal|May 31, 2024
Impact of Extraosseous Extramedullary Disease on Outcomes of Patients with Relapsed-Refractory Multiple Myeloma receiving Standard-of-Care Chimeric Antigen Receptor T-Cell TherapyDanai Dima, Al-Ola Abdallah, James A Davis, et al.
American Journal of Hematology|November 26, 2013
Mature results of MM-011: a phase I/II trial of liposomal doxorubicin, vincristine, dexamethasone, and lenalidomide combination therapy followed by lenalidomide maintenance for relapsed/refractory multiple myelomaAleksandr Lazaryan, Mohamad A Hussein, Frederic J Reu, et al.
Clinical Journal of Oncology Nursing|May 21, 2008
Management of side effects of novel therapies for multiple myeloma: consensus statements developed by the International Myeloma Foundation's Nurse Leadership BoardPage Bertolotti, Elizabeth Bilotti, Kathleen Colson, et al.
Pageof 6